Author:
Mohan Bhavika,Sharda Nishi,Singh Saranjit
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference5 articles.
1. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem
2. Anonymous, Pharmacopoeial Previews, Pharmacopeial Forum 26, Sept.–Oct. 2000, pp. 1420–1422.
3. Anonymous, Interim Revision Announcement, Pharmacopeial Forum 27, Nov.–Dec. 2001, pp. 3232–3233.
4. B. Mohan, Development of a stability indicating assay method for rifampicin, isoniazid and pyrazinamide in combination, MSc (Pharm.) thesis, NIPER, S.A.S. Nagar, India, 2001.
5. The Reason for an Increase in Decomposition of Rifampicin in the Presence of Isoniazid under Acid Conditions
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献